LSM-775

Source: Wikipedia, the free encyclopedia.
LSM-775
Clinical data
Other namesLSM-775, N-Morpholinyllysergamide, Lysergic acid morpholide
Routes of
administration		Oral
Legal status
Legal status
Pharmacokinetic data
Metabolismhepatic
Excretionrenal
Identifiers
  • (8β)-6-Methyl-8-(morpholin-4-ylcarbonyl)-9,10-didehydroergoline
JSmol)
  • O=C(N1CCOCC1)[C@@H]5C=C4c2cccc3c2c(c[nH]3)C[C@H]4N(C)C5
  • InChI=1S/C20H23N3O2/c1-22-12-14(20(24)23-5-7-25-8-6-23)9-16-15-3-2-4-17-19(15)13(11-21-17)10-18(16)22/h2-4,9,11,14,18,21H,5-8,10,12H2,1H3/t14-,18-/m1/s1 checkY
  • Key:OTQWCDNEJVKXKG-RDTXWAMCSA-N checkY
  (verify)

N-Morpholinyllysergamide (LSM-775) is a derivative of

cardiovascular stimulation and peripheral toxicity with LSM-775 compared to LSD.[3][dubious – discuss
]

See also

References

  1. ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants" [Order of May 20, 2021 amending the order of February 22, 1990 setting the list of substances classified as narcotics]. www.legifrance.gouv.fr (in French). 20 May 2021.
  2. PMID 13476356
    .
  3. ^ Shulgin A, Shulgin A. "TiHKAL #26, LSD-25". Erowid.


Retrieved from "https://en.wikipedia.org/w/index.php?title=LSM-775&oldid=1203745563"